– Bloomberg
Mizuho Maintains Buy on CVS Health, Raises Price Target to $120
Mizuho analyst Ann Hynes maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $115 to $120.
Related Posts
International Paper Gearing Up For Recovery With Optimistic Containerboard Market Trends: Analyst
Truist Securities analyst Michael Roxland upgraded International Paper Company (NYSE: IP) to Buy from Hold,
Flora Growth Corp. To Effect 1-For-20 Reverse Stock Split To Commence Trading On A Post-Reverse Stock Split Basis At Market Open On June 9, 2023
Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a global cultivator, manufacturer, and distributor of cannabis products and brands, announces that it will effect a reverse stock split,
What’s Going On With Fintech Company Affirm Holdings Stock On Wednesday?
PayPal co-founder Max Levchin's fintech company Affirm partners with Brittain Resorts & Hotels to offer flexible payment options for guests.